Join the Juvenile Rheumatoid Arthritis group to help and get support from people like you.
Juvenile Rheumatoid Arthritis News
Related terms: Juvenile Chronic Polyarthritis, JRA
FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra
JERSEY CITY, N.J., Jan. 30, 2025 – Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...
Childhood Maltreatment May Up Risk for Immune-Mediated Inflammatory Disorders
THURSDAY, Jan. 23, 2025 – On a global scale, childhood maltreatment is associated with a higher risk for developing some immune-mediated inflammatory disorders (IMIDs), according to a study...
More Than Half of People With Rheumatoid Arthritis Have Anemia
THURSDAY, Jan. 2, 2025 – Anemia is prevalent among patients with rheumatoid arthritis (RA), according to a study published online Oct. 26 in Cureus. Jamal Shah, M.B.B.S., from Khyber Teaching ...
Infertility Without Treatment Linked to Autoimmune Rheumatic Disease After Childbirth
TUESDAY, Dec. 10, 2024 – For women who give birth, infertility without fertility treatment is associated with an increased risk for incident systemic autoimmune rheumatic disease (SARD), according...
Socioeconomic Factors May Not Predict Rheumatoid Arthritis Disease Activity
THURSDAY, Dec. 5, 2024 – The impact of socioeconomic factors on disease activity in rheumatoid arthritis (RA) varies by academic or safety net hospital setting, according to a study published online...
FDA Approves Tofidence (tocilizumab-bavi), a Biosimilar to Actemra
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) – Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) intravenous...
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA)
South San Francisco, CA – September 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the...
FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a p...
Otrexup (Methotrexate) Injection Approved By FDA
EWING, N.J., October 14, 2013 — Antares Pharma, Inc. today announced the approval of Otrexup (methotrexate) injection by the U.S. Food and Drug Administration (FDA). Otrexup is the first FDA approved ...
Ilaris Approved by FDA to Treat Active Systemic Juvenile Idiopathic Arthritis
Basel, May 10, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis...
FDA Approves Actemra for Children with Polyarticular Juvenile Idiopathic Arthritis
BASEL, April 30, 2013 – Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis...
Further information
Related condition support groups
Juvenile Idiopathic Arthritis, Rheumatoid Arthritis
Related drug support groups
prednisone, ibuprofen, meloxicam, aspirin, Celebrex, Advil, Motrin, Enbrel, Mobic, dexamethasone, Arthritis Pain, etanercept